Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 14/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.36 |
| ▸ | JUN | P05412 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3741163 | 1.00 | MAPK10 (0.38) | MAPK10MAPK8JUNCNR2MAPK13 | |
| SCHEMBL3747282 | 0.86 | PSEN1 (0.43) | — | |
| SCHEMBL3747293 | 0.86 | PSEN1 (0.43) | — | |
| SCHEMBL3709472 | 0.82 | MAPK10 (0.34) | MAPK10CNR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3750045 | 0.82 | MAPT (0.39) | CNR2 | |
| SCHEMBL3745651 | 0.82 | ROCK2 (0.36) | CNR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3703629 | 0.81 | SLC6A4 (0.35) | MAPK10MAPK8JUNCNR2SLC6A2 | |
| SCHEMBL3750565 | 0.77 | CNR2 (0.33) | CNR2 | |
| SCHEMBL3750561 | 0.77 | CNR2 (0.33) | CNR2 | |
| SCHEMBL3706536 | 0.77 | PSEN1 (0.39) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| WO-2010132015-A1 | NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292210-A1 | Novel Compounds for A-Beta-Related Pathologies | BACE1, APP, BACE2 | MAPK10 2302/4885MAPK8 3630/4885JUN 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.